Department of Neuropsychiatry, Dongguk University Ilsan Hospital, Korea.
Int Clin Psychopharmacol. 2010 Mar;25(2):107-15. doi: 10.1097/YIC.0b013e3283364411.
We evaluated the effect of OROS methylphenidate (MPH) on sleep quality and architecture in children with attention-deficit/hyperactivity disorder (ADHD) using both a parental sleep questionnaire and polysomnography. Twenty-four ADHD children who had no comorbid psychiatric or sleep disorders except for oppositional defiant disorder completed the 6-week, prospective, open-label, flexible-dose trial with OROS MPH (Concerta) monotherapy. After OROS MPH administration, the polysomnography data indicated that the percentage of stage 2 sleep was increased (P=0.024) and the Number of Awakenings was decreased (P=0.047). Relative to baseline, Parasomnias of the Children's Sleep Habits Questionnaire were decreased (P=0.033). Sleep Onset Latency was not changed during the treatment in general, but was increased in six children with subjective sleep difficulties (F(1)=5.832, P=0.025, eta(2)(p)=0.226). Bedtime Resistance and Sleep Onset Delay in Children's Sleep Habits Questionnaire were also increased during the treatment with OROS MPH only in individuals with sleep complaints (F1=5.001, P=0.036, eta(2)(p)=0.185; F(1)=7.237, P=0.013, eta(2)(p)=0.248). These results suggest that OROS MPH in open-label treatment does not seem to impair sleep and may even improve some aspects of sleep.
我们采用父母睡眠问卷和多导睡眠图评估了 OROS 哌甲酯（MPH）对注意缺陷/多动障碍（ADHD）儿童睡眠质量和结构的影响。24 名 ADHD 儿童除对立违抗性障碍外，无共患精神或睡眠障碍，完成了为期 6 周、前瞻性、开放标签、灵活剂量的 OROS MPH（Concerta）单药治疗试验。在 OROS MPH 给药后，多导睡眠图数据表明，第 2 期睡眠的百分比增加（P=0.024），觉醒次数减少（P=0.047）。与基线相比，儿童睡眠习惯问卷中的睡眠障碍减少（P=0.033）。一般来说，治疗期间睡眠潜伏期没有变化，但在 6 名主观睡眠困难的儿童中增加（F(1)=5.832，P=0.025，eta(2)(p)=0.226）。在 OROS MPH 治疗期间，儿童睡眠习惯问卷中的上床抵抗和入睡延迟也仅在有睡眠抱怨的个体中增加（F1=5.001，P=0.036，eta(2)(p)=0.185；F(1)=7.237，P=0.013，eta(2)(p)=0.248）。这些结果表明，开放标签治疗中的 OROS MPH 似乎不会损害睡眠，甚至可能改善睡眠的某些方面。
